🇺🇸 FDA

Intelligence Platform

Patents

Browse 17 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11365230

Compositions comprising lentiviral vectors expressing IL-12 and methods of use thereof

IMMUNE DESIGN CORP. · Granted Tue Jun 21 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11135283

Retroviral vector for the administration and expression of replicon RNA expressing heterol

IMMUNE DESIGN CORP. · Granted Tue Oct 05 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10993999

Materials and methods for producing improved lentiviral vector particles

IMMUNE DESIGN CORP. · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10993956

GLA monotherapy for use in cancer treatment

IMMUNE DESIGN CORP. · Granted Tue May 04 2021 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 29 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10584356

Multigenome retroviral vector preparations and methods and systems for producing and using

IMMUNE DESIGN CORP. · Granted Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10391157

Materials and methods for producing improved lentiviral vector particles

IMMUNE DESIGN CORP. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10391164

Vaccines for HSV-2

IMMUNE DESIGN CORP. · Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10342815

GLA monotherapy for use in cancer treatment

IMMUNE DESIGN CORP. · Granted Tue Jul 09 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 04 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10179919

Multigenome retroviral vector preparations and methods and systems for producing and using

IMMUNE DESIGN CORP. · Granted Tue Jan 15 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 10 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9895435

Vaccines for HSV-2

IMMUNE DESIGN CORP. · Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9713635

Materials and methods for producing improved lentiviral vector particles

IMMUNE DESIGN CORP. · Granted Tue Jul 25 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 20 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9555099

Vaccines for HSV-2

IMMUNE DESIGN CORP. · Granted Tue Jan 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 26 2037 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9044420

Immunogenic compositions and methods of using the compositions for inducing humoral and ce

IMMUNE DESIGN CORP. · Granted Tue Jun 02 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8962593

GLA monotherapy for use in cancer treatment

IMMUNE DESIGN CORP. · Granted Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8957047

GLA monotherapy for use in cancer treatment

IMMUNE DESIGN CORP. · Granted Tue Feb 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 12 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8323662

Methods useful for generating highly mannosylated pseudotyped lentiviral vector particles

IMMUNE DESIGN CORP. · Granted Tue Dec 04 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 29 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 8187872

Lentiviral vectors pseudotyped with a sindbis virus envelope glycoprotein

IMMUNE DESIGN CORP. · Granted Tue May 29 2012 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 24 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

granted